AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Insider Transactions Reported | 10x Genomics(TXG)saw insider trading activity on 8/26/2025
ByAinvest
Tuesday, Aug 26, 2025 10:00 pm ET1min read
10x Genomics(TXG) saw insider trading activity on 8/26/2025, there were 3 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 8/26/2025 | Chief Executive Officer | Saxonov Serge | Sell | 9348 | 13.79 | 128.88k |
| 8/26/2025 | President and Chief Scientific Officer | Hindson Benjamin J. | Sell | 7486 | 13.79 | 103.21k |
| 8/26/2025 | Chief Financial Officer | Taich Adam | Sell | 22315 | 13.79 | 307.66k |
| 5/27/2025 | Chief Financial Officer | Taich Adam | Sell | 4044 | 8.30 | 33.56k |
| 5/27/2025 | Chief Executive Officer | Saxonov Serge | Sell | 9343 | 8.30 | 77.54k |
| 5/27/2025 | President and Chief Scientific Officer | Hindson Benjamin J. | Sell | 7485 | 8.30 | 62.12k |
| 3/4/2025 | Chief Executive Officer | Saxonov Serge | Sell | 7942 | 10.63 | 84.39k |
| 3/4/2025 | Chief Executive Officer | Saxonov Serge | Buy | 50000 | 1.20 | 60.0k |
| 2/26/2025 | Chief Executive Officer | Saxonov Serge | Sell | 5092 | 11.07 | 56.35k |
| 2/26/2025 | President and Chief Scientific Officer | Hindson Benjamin J. | Sell | 4573 | 11.07 | 50.6k |
[Company Profile]
10x Genomics, Inc. was incorporated in the state of Delaware on July 2, 2012. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company's integrated solutions include the Company's Chromium instruments, which are referred to as “instruments”, its enzymes, reagents, microfluidic chips and other consumable products, which are referred to as “consumables”, and software for analyzing biological systems.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet